All In Biotech

Drug Trial Radar · NCT03660059

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX

Last checked: Nov 20, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 385 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

385

Actual

Start

Sep 27, 2018

Primary completion

Apr 1, 2021

Study completion Nov 2, 2021

Sponsor

Lead sponsor
Astellas Pharma China, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Sep 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response or intolerance to MTX, as measured by the American College of Rheumatology (ACR) 20 response rate at Week 24. This study will also evaluate the pharmacokinetics and safety of ASP015K as well as efficacy and safety of long-term treatment with ASP015K (52 weeks).

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • PeficitinibDrug

    Oral

  • PlaeboDrug

    Oral

  • Disease-modifying antirheumatic drugs (DMARDs)Drug

    As necessary concomitant medications, DMARDs listed below will be administered orally unless specified. For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology (ACR)20 response rate at Week 24Time frame: At Week 24

Locations

43 sites in 3 countries. Site status is shown where the registry gives one.

  • Site CN00048

    Anhui, China

  • Site CN00045

    Beijing, China

  • Site CN00054

    Beijing, China

  • Site CN00050

    Bengbu, China

  • Site CN00061

    Changchun, China

  • Site CN00032

    Changsha, China

  • Site CN00076

    Chenzhou, China

  • Site CN00071

    Guangdong, China

  • Site CN00016

    Guangzhou, China

  • Site CN00052

    Guangzhou, China

  • Site CN00063

    Guangzhou, China

  • Site CN00072

    Guangzhou, China

  • Site CN00058

    Inner Mongolia, China

  • Site CN00074

    Jieyang, China

  • Site CN00028

    Jilin City, China

  • Site CN00069

    Jining, China

  • Site CN00064

    Jiujiang, China

  • Site CN00046

    Kunming, China

  • Site CN00060

    Nanjing, China

  • Site CN00070

    Nanjing, China

  • Site CN00068

    Ningbo, China

  • Site CN00075

    Pingxiang, China

  • Site CN00066

    Qingdao, China

  • Site CN00056

    Shanghai, China

  • Site CN00047

    Shantou, China

  • Site CN00053

    Sichuan, China

  • Site CN00057

    Tianjin, China

  • Site CN00062

    Tianjin, China

  • Site CN00059

    Wuhan, China

  • Site CN00067

    Xining, China

  • Site CN00065

    Xuzhou, China

  • Site CN00073

    Zhengzhou, China

  • Site CN00049

    Zhuzhou, China

  • Site KR00037

    Gwangju, South Korea

  • Site KR00036

    Incheon, South Korea

  • Site KR00033

    Seoul, South Korea

  • Site KR00034

    Seoul, South Korea

  • Site KR00035

    Seoul, South Korea

  • Site TW00022

    Taichung, Taiwan

  • Site TW00023

    Taichung, Taiwan

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.